Comparative Pharmacology
Head-to-head clinical analysis: INFLAMASE FORTE versus OPHTHOCORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INFLAMASE FORTE versus OPHTHOCORT.
INFLAMASE FORTE vs OPHTHOCORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
OPHTHOCORT contains chloramphenicol, a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation; and hydrocortisone, a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene synthesis.
1-2 tablets (ibuprofen 400mg / pseudoephedrine 60mg) orally every 6 hours as needed; maximum 6 tablets per day.
One drop into the affected eye(s) every 3-4 hours, or more frequently as needed. In severe cases, one drop every hour. Shake well before use.
None Documented
None Documented
Terminal half-life 36–42 hours in patients with normal renal function; prolonged to 18–26 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Terminal elimination half-life: 2.5-3.5 hours in adults with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Approximately 95% renal: 90% as unchanged drug via glomerular filtration and tubular secretion, 5% as minor metabolites; 5% fecal via biliary elimination.
Renal (70-80% as unchanged drug), fecal (15-20% via biliary elimination), with minor metabolic clearance.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid/Antibiotic Combination